secwatch.observer — SEC 8-K summary
======================================

Issuer:     RxSight, Inc. (RXST)
CIK:        0001111485
Form:       8-K
Filed at:   2025-02-25T23:59:59+00:00
Accession:  0000950170-25-026651
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

RxSight Q4 revenue $40.2M (+41% YoY), LAL volume +61%; reaffirms FY2025 guidance
--------------------------------------------------------------------------------

- Q4 revenue $40.2M (+41% YoY); full-year revenue $139.9M (+57% YoY).
- Q4 net loss $(5.9)M vs $(9.2)M; adjusted net earnings $1.3M ($0.03/share) vs adjusted loss $(4.8M).
- LAL procedure volume 29,069 units (+61% YoY); LDD installed base 971 (+46% YoY).
- FY2025 guidance: revenue $185-197M (32-41% growth), gross margin 71-73%, operating expenses $165-170M.
- Cash and investments $237.2M; no debt mentioned.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1111485/000095017025026651/0000950170-25-026651-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1111485/000095017025026651/rxst-20250225.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-026651

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer